Researchers have found a link between low testosterone levels and aggressive tumors, which could change how prostate cancer ...

Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), acc ...

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

USA: A retrospective cohort study has found that low testosterone levels in patients with prostate cancer undergoing active ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Results challenge view that high testosterone fuels prostate cancer growth ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

Early detection plays a major role in recovering from cancer. Dr Chawla shares five symptoms that can help people over 50 ...

Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.